Sibutramine produces dose-related weight loss
Sibutramine produces dose-related weight loss
复制标题
DOI：
10.1002/j.1550-8528.1999.tb00701.x
复制
发表时间：
1999-03-01
期刊：
影响因子：
--
通讯作者：
Seaton, TB
中科院分区：
文献类型：
--
作者：
Bray, GA;Blackburn, GL;Seaton, TB
目的：西布曲明是一种体重控制药物，可抑制5-羟色胺和去甲肾上腺素的再摄取。在动物身上，它减少了食物的摄入量，增加了产热能力，初步数据显示，在人类身上体重过高。本文报道了一项为期24周的剂量范围研究，以确定西布曲明对肥胖患者体重的影响。研究方法NOD程序：7个临床中心筛查1463名肥胖症患者，随机接受1047-24周的治疗，每天1次，共6剂西布曲明(1，5，10，15，20或30 mg)或安慰剂。683名患者完成了这项研究。为期两周的安慰剂磨合期被用来启动一项关于饮食、体力活动和生活方式改变的标准化计划。结果：体重减轻与剂量相关，与安慰剂相比具有统计学意义(p
Objective: Sibutramine is a weight control drug that inhibits the reuptake of both serotonin and norepinephrine. In animals, it reduces food intake and increases thermogenesis and preliminary data in human beings showed weight lass. This paper reports a 24-week dose-ranging study to determine the effect of sibutramine on body weight of patients with obesity.Research Methods nod Procedures: Seven clinical centers screened 1463 patients with obesity and randomized 1047 to 24 weeks of treatment with I of 6 doses of sibutramine (1, 5, 10, 15, 20, or 30 mg) or placebo once daily. Six hundred eighty-three patients completed the study. A two-week placebo run-in period was used to initiate a standardized program of diet, physical activity, and lifestyle changes.Results: Weight loss was dose-related and statistically significant vs. placebo (p